Selected by the NSW State Government, Australia, to spend two years (2015-17) based at the UCSF-based QB3 Rosenman Institute in San Francisco, Sheridan and Michael founded Cenofex Innovations to develop and deliver a medical device that will transform the treatment of lymphoedema.
Through the extensive QB3 network, Sheridan and Michael developed key collaborations spanning technology, clinical, patient, and business sectors. The founders worked closely with the UCSF's academic clinicians to refine their device design inputs, and re-invented the device technology to better satisfy these inputs. Using the QB3 facilities, they refined their device prototype, designed and built verification tools for their innovative technology, and conducted initial testing in a laboratory environment.
In 2018, Michael and Sheridan returned to Australia where Cenofex Innovations continues to pursue the development and commercialisation of their medical device in NSW.